FIP1L1/PDGFRα-Associated systemic mastocytosis

International Archives of Allergy and Immunology

Volumn 152, Issue SUPPL. 1, 2010, Pages 101-105

  Yamada, Yoshiyuki ^a   Cancelas, Jose A ^b,c  

^a Gumna Children S Medical Center   (Japan)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Chronic eosinophilic leukemia; Eosinophils; FIP1L1 PDGFR ; Hypereosinophilic syndromes; Interleukin 5; Mast cells; Stem cell factor; Systemic mastocytosis

Indexed keywords

HYBRID PROTEIN; IMATINIB; INTERLEUKIN 5; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN FIP1L1; STEM CELL FACTOR; UNCLASSIFIED DRUG;

CELL INFILTRATION; CELL MATURATION; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE MODEL; EOSINOPHIL; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; GENE OVEREXPRESSION; HUMAN; HYPEREOSINOPHILIC SYNDROME; IN VITRO STUDY; MAST CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INTERACTION; SYSTEMIC MASTOCYTOSIS;

ANIMALS; EOSINOPHILIA; HUMANS; MASTOCYTOSIS, SYSTEMIC; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 77953282156     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000312134     Document Type: Conference Paper

References (25)

1. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.
2. Curtis CE, Grand FH, Musto P, Clark A, Murphy J, Perla G, Minervini MM, Stewart J, Reiter A, Cross NC: Two novel imatinibresponsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol 2007; 138: 77-81.
3. Score J, Curtis C, Waghorn K, Stalder M, Jotterand M, Grand FH, Cross NC: Identification of a novel imatinib-responsive KIF5BPDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006; 20: 827-832.
4. Walz C, Curtis C, Schnittger S, Schultheis B, Metzgeroth G, Schoch C, Lengfelder E, Erben P, Muller MC, Haferlach T, Hochhaus A, Hehlmann R, Cross NC, Reiter A: Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9; 4) (q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer 2006; 45: 950-956.
5. Tefferi A, Vardiman JW: Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
6. Gotlib J, Cools J: Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008; 22: 1999-2010.
7. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, Curley DP, Duclos N, Rowan R, Kutok JL, Lee BH, Williams IR, Coutre SE, Stone RM, DeAngelo DJ, Marynen P, Manley PW, Meyer T, Fabbro D, Neuberg D, Weisberg E, Griffin JD, Gillil and DG: PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 2003; 3: 459-469.
8. Yamada Y, Rothenberg ME, Lee AW, Akei HS, Brandt EB, Williams DA, Cancelas JA: The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood 2006; 107: 4071-4079.
9. Yamada Y, Sanchez-Aguilera A, Brandt EB, McBride M, Al-Moamen NJ, Finkelman FD, Williams DA, Cancelas JA, Rothenberg ME: FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome. Blood 2008; 112: 2500-2507.
10. Maric I, Robyn J, Metcalfe DD, Fay MP, Carter M, Wilson T, Fu W, Stoddard J, Scott L, Hartsell M, Kirshenbaum A, Akin C, Nutman TB, Noel P, Klion AD: KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 2007; 120: 680-687.
11. Pardanani A, Reeder T, Li CY, Tefferi A: Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res 2003; 27: 883-885.
12. Lawrence JB, Friedman BS, Travis WD, Chinchilli VM, Metcalfe DD, Gralnick HR: Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 1991; 91: 612-624.
13. Rothenberg ME, Hogan SP: The eosinophil. Annu Rev Immunol 2006; 24: 147-174.
14. Patnaik MM, Rindos M, Kouides PA, Tefferi A, Pardanani A: Systemic mastocytosis: a concise clinical and laboratory review. Arch Pathol Lab Med 2007; 131: 784-791.
15. Klion AD: How I treat hypereosinophilic syndromes. Blood 2009; 114: 3736-3741.
16. Cools J, Quentmeier H, Huntly BJ, Marynen P, Griffin JD, Drexler HG, Gilliland DG: The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2004; 103: 2802-2805.
17. Burgstaller S, Kreil S, Waghorn K, Metzgeroth G, Preudhomme C, Zoi K, White H, Cilloni D, Zoi C, Brito-Babapulle F, Walz C, Reiter A, Cross NC: The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus. Leukemia 2007; 21: 2428-2432.
18. Iwasaki H, Mizuno S, Mayfield R, Shigematsu H, Arinobu Y, Seed B, Gurish MF, Takatsu K, Akashi K: Identification of eosinophil lineage-committed progenitors in the murine bone marrow. J Exp Med 2005; 201: 1891-1897.
19. Arinobu Y, Iwasaki H, Akashi K: Origin of basophils and mast cells. Allergol Int 2009; 58: 21-28.
20. Yuan Q, Austen KF, Friend DS, Heidtman M, Boyce JA: Human peripheral blood eosinophils express a functional c-kit receptor for stem cell factor that stimulates very late antigen 4 (VLA-4)-mediated cell adhesion to fibronectin and vascular cell adhesion molecule 1 (VCAM-1). J Exp Med 1997; 186: 313-323.
21. Dahl C, Hoffmann HJ, Saito H, Schiotz PO: Human mast cells express receptors for IL-3, IL-5 and GM-CSF; a partial map of receptors on human mast cells cultured in vitro. Allergy 2004; 59: 1087-1096.
22. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A: CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102: 3093-3096.
23. Robyn J, Lemery S, McCoy JP, Kubofcik J, Kim YJ, Pack S, Nutman TB, Dunbar C, Klion AD: Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Br J Haematol 2006; 132: 286-292.
24. Tefferi A, Lasho TL, Brockman SR, Elliott MA, Dispenzieri A, Pardanani A: FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica 2004; 89: 871-873.
25. Adachi T, Hanaka S, Yano T, Yamamura K, Yoshihara H, Nagase H, Chihara J, Ohta K: The role of platelet-derived growth factor receptor in eotaxin signaling of eosinophils. Int Arch Allergy Immunol 2006; 140(suppl 1):28-34.